scholarly journals Optical Frequency Domain Imaging to Reveal an Angiographically Inapparent Very Late Stent Thrombosis as the Cause of an Acute Coronary Syndrome

2012 ◽  
Vol 60 (7) ◽  
pp. e11
Author(s):  
Milosz Jaroslaw Jaguszewski ◽  
Silke Kuest ◽  
Christian Templin ◽  
Ulf Landmesser
2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Raghavendra Rao K ◽  
S. Reddy ◽  
J. R. Kashyap ◽  
K. Vikas ◽  
Hithesh Reddy ◽  
...  

Very late stent thrombosis (VLST) is a catastrophic and life-threatening complication after percutaneous coronary intervention which presents as an acute coronary syndrome with significantly high mortality and morbidity. VLST is a rare entity with drug-eluting stents and even rarer with bare metal stents. The exact pathophysiologic mechanism of VLST after BMS implantation is not known although various mechanisms have been proposed. Recently, in-stent neoatherosclerosis with intimal plaque rupture has been proposed as a potential mechanism of VLST after BMS. We report a rare case of VLST occurring 17 years after BMS implantation with angiographic and intravascular imaging evidence which provides insight into the mechanisms of VLST.


2017 ◽  
Vol 58 (1) ◽  
pp. 131-133 ◽  
Author(s):  
Yutaka Goryo ◽  
Teruyoshi Kume ◽  
Yusuke Kobayashi ◽  
Hiroshi Okamoto ◽  
Ai Kawamura ◽  
...  

2017 ◽  
Vol 5 ◽  
pp. 2050313X1772405
Author(s):  
Toshiki Kuno ◽  
Kenji Hashimoto ◽  
Syohei Imaeda ◽  
Toshinobu Ryuzaki ◽  
Tetsuya Saito ◽  
...  

Objectives: A calcified thrombus is rare, but needs to be recognized and to be differentiated from calcified nodule. Methods: We report a case of acute coronary syndrome and a large intracoronary mobile mass, which was identified as a calcified thrombus by optical frequency domain imaging and intravascular ultrasound. Results: Successful direct stenting indicated that mobile mass was a calcified thrombus, not a calcified nodule. Conclusions: Cardiologists should be aware that an intracoronary mobile mass could be a calcified thrombus. This diagnosis can be confirmed through the combined use of optical frequency domain imaging and intravascular ultrasound.


2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
T Konishi

Abstract Background The relationship between eicosapentaenoic acid (EPA) therapy and coronary plaque stability assessed by optical frequency domain imaging (OFDI) has not been thoroughly described. Hypothesis EPA therapy is associated with decreased plaque instability in patients undergoing percutaneous coronary intervention (PCI) using OFDI. Methods Data on coronary artery plaques from 121 patients presenting with acute coronary syndrome or stable angina who consecutively underwent PCI between October 2015 and July 2018 were retrospectively analyzed. Of these patients, 109 were untreated (no-EPA group), whereas 12 were treated with EPA (EPA group). Each plaque's morphological characteristics were analyzed using OFDI. Results We used 1:4 propensity score matching for patients who received or did not receive EPA therapy before PCI. Baseline characteristics were balanced between both groups (age, sex, body mass index, diabetes mellitus, hypertension, dyslipidemia, chronic kidney disease, smoking, previous PCI or coronary artery bypass grafting, previous myocardial infarction, prior statin use, acute coronary syndrome, hemoglobin A1c level, low-density lipoprotein cholesterol concentration, triglyceride concentration, and high-density lipoprotein cholesterol concentration). The EPA group had significantly lower mean lipid index (818±806 vs. 1,574±891) and macrophage grade (13.5±5.9 vs. 19.3±7.4) but higher mean minimum fibrous cap thickness (109.2±55.7 vs. 81.6±36.4 μm) than the no-EPA group (P=0.010, 0.019, and 0.040, respectively). Multiple logistic regression analyses showed that prior EPA use was independently associated with lower lipid index and macrophage grade (P=0.043 and 0.024, respectively). Conclusion This OFDI analysis suggests that EPA therapy is associated with decreased plaque instability in patients undergoing PCI. Acknowledgement/Funding None


2013 ◽  
Vol 2013 ◽  
pp. 1-2 ◽  
Author(s):  
Mariana Soto Herrera ◽  
José A. Restrepo ◽  
Andrés Felipe Buitrago ◽  
Mabel Gómez Mejía ◽  
Jesús H. Díaz

Very late stent thrombosis is a rare and not-well-understood complication after bare metal stent implantation. It usually presents as an ST elevation acute coronary syndrome and it is associated with high rates of morbidity and mortality. Pathophysiologic mechanisms are not well defined; nevertheless, recent studies have proposed a neoatherosclerotic process as the triggering mechanism. We present the case of a patient with bare metal very late stent thrombosis 12 years after implantation.


Author(s):  
Shekhar Kunal ◽  
Vijay Pathak ◽  
Keshav Pathak ◽  
Monika Mishra ◽  
Shashi Mohan Sharma ◽  
...  

Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 has varied manifestation with multisystem involvement. Acute coronary syndrome in COVID-19 as a result of stent thrombosis is an uncommon entity and is often due to hypercoagulable state. A 40-year-old male was referred to us with acute onset chest pain. He also reported fever, sore throat and dry cough for six days which mandated testing for COVID-19 which turned out to be positive. He had a prior history of coronary artery disease with a drug eluting stent implanted two years back. An electrocardiogram was suggestive of acute anterior wall myocardial infarction while echocardiogram revealed hypokinesia of left anterior descending (LAD) artery territory. Coronary angiogram revealed non-occlusive thrombus in proximal LAD stent. A Thrombolysis in Myocardial Infarction (TIMI) III flow was restored following balloon angioplasty with a non-compliant balloon and use of glycoprotein (GP) IIb-IIIa receptor antagonist. A diagnosis of very late stent thrombosis subsequent to COVID-19 was made.


Sign in / Sign up

Export Citation Format

Share Document